Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 6/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 8/20 | 0.45 |
| ▸ | JAK1 | P23458 | 7/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31403755 | 1.00 | NUDT1 (0.50) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL1082037 | 0.84 | AXL (0.47) | NUDT1AXLMAP2K1PRKCIJAK3 | |
| SCHEMBL31403683 | 0.83 | JAK3 (0.46) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL21632535 | 0.83 | JAK3 (0.46) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL29656385 | 0.83 | TTBK1 (0.48) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL25280494 | 0.83 | AXL (0.46) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL30985188 | 0.83 | AXL (0.55) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL2115690 | 0.83 | AXL (0.55) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL28798529 | 0.83 | TTBK1 (0.48) | NUDT1AXLMAP2K1TTBK1TTBK2 | |
| SCHEMBL24495812 | 0.83 | JAK2 (0.53) | NUDT1AXLPRKCIJAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | HELICON THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | GABRA5, GABRA6, GABRB1 | NUDT1 4256/4885AXL 4156/4885MAP2K1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.